3-D Vision Brings New Perspectives
When Edna Cukierman, PhD, obtained an independent research position and decided to apply for a cancer research grant, she had one problem: “I didn’t know anything about cancer,” she recalls.
Search/Filter
Loading...
How the AACR-Novocure TTFields Research Grant Opens Doors
The AACR-Novocure Tumor Treating Fields Research Grants represent a joint effort to promote and support innovative research focused on Tumor Treating Fields (TTFields), which are intermediate frequency, low intensity, alternating electric fields that disrupt cell division in cancer cells. 2020 grant recipient Carsten Hagemann, PhD, shares his perspectives on the myriad benefits of the grant.
Ravi Majeti and the Elusive Cells
After undergraduate education at Harvard University, Ravi Majeti earned his MD and PhD at University of California San Francisco. He took an interest in acute myeloid leukemia (AML) in medical school and cared for patients with AML during his residency in internal medicine at Brigham and Women’s Hospital in Boston and Hematology fellowship at Stanford University...
From Bench to Community: Dr. Channing Der on PanCAN-AACR Grants Impact
Dr. Channing Der serves as the Sarah Graham Kenan Professor of Pharmacology at the Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill. Having received his PhD from the University of California at Irvine, Dr. Der went on to complete his postdoctoral research training at the Dana-Farber Cancer Institute and Harvard Medical School. As a two-time PanCAN-AACR grant recipient...
“Everyone Said it Wouldn’t Work,” but an AACR Grant Helped Michael Jensen Prove Otherwise
For Michael Jensen, MD, a grant from the AACR came at a good time. It was 1996, and Jensen was at the Fred Hutchinson Cancer Research Center in Seattle for his fellowship as a pediatric oncologist-hematologist, working in the laboratory of....
Dr. Sonia del Rincón on SU2C Dream Team Grant Impact
Dr. Sonia del Rincón and the Stand Up to Cancer (SU2C) Canada Metastatic Breast Cancer Dream Team are looking to understand the impact of MAP kinase–interacting serine/threonine kinases 1 and 2 (MNK1/2) inhibitors on metastatic breast cancer...